Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shenzhen (SZSE) — 凯莱英
Other Market Stock Code002821
H-Share Offer PriceHK$ 388.00
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameAsymchem
Stock Code06821
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是領先的技術驅動型CDMO公司,提供貫穿藥物開發及生產全過程的綜合解決方案。就小分子藥物提供貫穿臨床前、臨床及商業化階段的工藝開發及生產服務,並將CDMO能力擴展至多肽、寡核苷酸、單克隆抗體(mAb)、抗體偶聯藥物(ADC)及信使RNA (mRNA),以及其他服務,包括藥物製劑解決方案、生物合成解決方案和臨床CRO解決方案。
Listing Date2021-12-10
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國天津市經濟技術開發區洞庭三街6號
Business Address (Hong Kong)香港灣仔皇后大道東248號大新金融中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.asymchem.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 388.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size100 shares
Entry ThresholdHK$ 38,800
Par ValueRMB 1.0 / shares
Offer Period2021-11-30 to 2021-12-03
Global Offering Shares18,415,400 shares
HK Public Offer Shares (Initial)1,841,600 shares (10.0%)
Public Offer Lots (Initial)18,416lots (Pool A9,208lots,Pool B9,208lots)
International Placing Shares (Initial)16,573,800 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO263,076,518 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 7,145,175,200

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 38,800
2 lots 200 HK$ 77,600
3 lots 300 HK$ 116,400
4 lots 400 HK$ 155,200
5 lots 500 HK$ 194,000
6 lots 600 HK$ 232,800
7 lots 700 HK$ 271,600
8 lots 800 HK$ 310,400
9 lots 900 HK$ 349,200
10 lots 1,000 HK$ 388,000
15 lots 1,500 HK$ 582,000
20 lots 2,000 HK$ 776,000
25 lots 2,500 HK$ 970,000
30 lots 3,000 HK$ 1,164,000
35 lots 3,500 HK$ 1,358,000
40 lots 4,000 HK$ 1,552,000
45 lots 4,500 HK$ 1,746,000
50 lots 5,000 HK$ 1,940,000
60 lots 6,000 HK$ 2,328,000
70 lots 7,000 HK$ 2,716,000
80 lots 8,000 HK$ 3,104,000
90 lots 9,000 HK$ 3,492,000
100 lots 10,000 HK$ 3,880,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
150 lots 15,000 HK$ 5,820,000
200 lots 20,000 HK$ 7,760,000
250 lots 25,000 HK$ 9,700,000
300 lots 30,000 HK$ 11,640,000
400 lots 40,000 HK$ 15,520,000
450 lots 45,000 HK$ 17,460,000
500 lots 50,000 HK$ 19,400,000
600 lots 60,000 HK$ 23,280,000
6,000 lots 600,000 HK$ 232,800,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 3.03B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 102,073,688,984
H-Share Market Cap (at Offer Price)HK$ 7,145,175,200
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币719.7百万元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201820192020
Revenue 1,822,7872,445,8493,136,724
Cost of sales -984,677-1,345,286-1,683,500
Gross profit 838,1101,100,5631,453,224
Other income and gains, net 79,306100,482119,773
Selling and distribution expenses -71,367-82,827-84,253
Administrative expenses -214,901-275,599-320,599
Net finance costs -1,467-1,768-3,728
Share of associates and JVs 01,4692,084
Profit before tax 460,498620,554811,233
Income tax expense -54,141-68,965-91,530
Profit for the year 406,357551,589719,703
Profit attributable to owners 428,202551,589719,742
Balance Sheet
Item 2018201920202021-06
Cash and cash equivalents 629,971435,2522,124,615
Trade and bills receivables 521,396656,908978,149
Inventories 424,117448,783726,384
Total current assets 1,694,2291,638,6284,030,548
Total assets 3,188,0763,788,0537,182,650
Total current liabilities 540,604507,437928,583
Total liabilities 677,688745,0041,192,900
Total equity 2,510,3883,043,0495,989,750
Equity attributable to owners 2,510,3883,043,0495,989,789
Interest-bearing borrowings 0010,0340
Cash Flow Statement
Item 2018201920202021-06
Net cash from operating activities 415,899602,034572,913
Net cash from investing activities -583,702-729,898-1,101,772
Depreciation of PP&E 100,948120,697153,97793,351
Depreciation of right-of-use assets 2,4965,2127,7726,311
Amortisation of intangible assets 1,2562,1893,5851,955
Purchase of PP&E -543,158-510,752-1,014,960-575,569
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 370.0
First Day OpenHK$ 388.0
First Day Change-4.64%
First Day Volume2786450.0
First Day Turnover1047110000.0
Use of Proceeds
1、約20%(或1,370.0百萬港元)將用于進一步提高我們的小分子CDMO解決方案的產能及能力; 2、約35%(或2,397.4百萬港元)將用于加強我們新興服務并擴大我們的服務內容; 3、約20%(或或1,370.0百萬港元)將用于投資研發項目及保持我們的技術領先地位; 4、約15%(或1,027.5百萬港元)將用于選擇性地進行戰略投資及收購; 5、約10%(或685.0百萬港元)將用作營運資金及一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中信证券(香港)有限公司 CE AAK249
Overall Coordinators (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893
Joint Bookrunners (6)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 Credit Suisse (Hong Kong) Limited CE AAO017 Citigroup Global Markets Asia Limited CE AAA137 国泰君安证券(香港)有限公司 CE ABY236 交银国际证券有限公司 CE APJ121
Joint Lead Managers (6)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CLSA LIMITED CE AAB893 Credit Suisse (Hong Kong) Limited CE AAO017 Citigroup Global Markets Asia Limited CE AAA137 国泰君安证券(香港)有限公司 CE ABY236 交银国际证券有限公司 CE APJ121

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
ChairmanHao Hong—
Company Secretary徐向科、鄭程傑—
No director data available.

Major Shareholders

Major Shareholders & HoldingsHao Hong博士通過ALAB持有88,510,520股A股(36.18%),並直接持有10,191,928股A股(4.17%);ALAB直接持有88,510,520股A股(36.18%)
About this page

This page shows Asymchem (06821) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect